Esperion Therapeutics (ESPR) Cash from Investing Activities Growth (1y) (2013 - 2024)
Esperion Therapeutics (ESPR) Cash from Investing Activities Growth (1y) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.93% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 57.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -186.78% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 551.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 526.11% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -3,664.79% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -3.45% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -100.44% |
| Mar 31, 2024 | -100.29% |
| Jun 30, 2023 | 250.00% |
| Mar 31, 2023 | 238.11% |
| Dec 31, 2022 | 76.64% |
| Dec 31, 2021 | -298.26% |
| Dec 31, 2020 | -341.98% |
| Sep 30, 2020 | 143.91% |
| Jun 30, 2020 | -80.87% |
| Mar 31, 2020 | -41.81% |
| Dec 31, 2019 | -107.44% |
| Sep 30, 2019 | -113.27% |
| Jun 30, 2019 | -15.38% |
| Mar 31, 2019 | 50.90% |
| Dec 31, 2018 | -20.31% |
| Sep 30, 2018 | 131.39% |
| Jun 30, 2018 | 16.48% |
| Mar 31, 2018 | 87.30% |
| Dec 31, 2017 | 524.34% |
| Sep 30, 2017 | -1,075.69% |